As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...

While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Phase III data for dapirolizumab pegol presented at the 2025 American College of Rheumatology showed quality-of-life benefits ...

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...